Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419445
Status:
COMPLETED
Last Update Posted:
2010-09-10
First Post:
2007-01-04
Brief Title:
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
Sponsor:
CoMentis
Organization:
CoMentis
Study Overview
Official Title:
A Double-Blind Randomized Proof-of-Concept Crossover Trial to Assess the Effects of GTS21 on Cognitive Function Clinical Symptoms and Adverse Events in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will be a randomized double-blind placebo-controlled crossover study to assess the effects of GTS21 25 mg three times a day tid 75 mg tid 150 mg tid compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD any subtype
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None